The association of malignant hyperthermia and unusual disease: When you're hot you're hot or maybe not

Anesthesia and Analgesia

Volumn 109, Issue 4, 2009, Pages 1001-1003

  Davis, Peter J ^a   Brandom, Barbara W ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; HALOTHANE; RYANODINE RECEPTOR 1;

ANESTHESIA INDUCTION; DISEASE ASSOCIATION; EDITORIAL; GENERAL ANESTHESIA; HEAT INJURY; INBORN ERROR OF METABOLISM; MALIGNANT HYPERTHERMIA; MUSCLE BIOPSY; MUSCLE CONTRACTURE; MUSCULAR DYSTROPHY; MYOTONIA; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; SYMPTOM; ANESTHESIA; BIOPSY; CHILD; EVIDENCE BASED MEDICINE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MUSCLE DISEASE; PATHOLOGY; PREDICTION AND FORECASTING; RARE DISEASE; RISK ASSESSMENT; RISK FACTOR;

ANESTHESIA; BIOPSY; CHILD; EVIDENCE-BASED MEDICINE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALIGNANT HYPERTHERMIA; MUSCULAR DISEASES; PREDICTIVE VALUE OF TESTS; RARE DISEASES; RISK ASSESSMENT; RISK FACTORS;

EID: 70349572483     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e3181b493d4     Document Type: Editorial

References (14)

1. Klinger W, Rueffert H, Lehmann-Horn F, Girard T, Hopkins P. Core myopathies and risk of malignant hyperthermia. Anesth Analg 2009;109:1167-1173
2. Capacchione JF, Capacchione J. The relationship between exertional heat illness, exertional rhabdomyolysis and malignant hyperthermia. Anesth Analg. In press
3. Parness J, Bandschapp O, Girard T. The myotonias and susceptibility to malignant hyperthermia. Anesth Analg. In press
4. Gurnaney H, Gurnaney H, Brown A, Litman R. Malignant hyperthermia and the musculardystrophies. Anesth Analg. In press
5. Benca J, Hogan K. Malignant hyperthermia, co-existing disorders and enzymopathies: risks and management options. Anesth Analg. In press
6. Brady JE, Sun LS, Rosenberg H, Li G. The prevalence of malignant hyperthermia related to exposure to anesthesia in New York State, 2001 to 2005. Anesth Analg. In press
7. Hogan K, Vladuliu GD, Vladutiu G. Malignant hyperthermialike syndrome and carnitine palmitoyltransferase II deficiency with heterozygous R503C mutation. Anesth Analg. In press
8. Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. Anesthesiology 1998;88:579-588
9. Larach MG, Landis JR, Bunn JS, Diaz M. Prediction of malignant hyperthermia susceptibility in low-risk subjects. An epidemiologic investigation of caffeine halothane contracture responses. Anesthesiology 1992;76:16-27
10. Heytens L, Martin JJ, Van de Kelft E, Bossaert LL. In vitro contracture tests in patients with various neuromuscular diseases. Br J Anaesth 1992;68:72-75
11. Gronert GA, Fowler W, Cardinet GH III, Grix A Jr, Ellis WG, Schwartz MZ. Absence of malignant hyperthermia contractures in Becker-Duchenne dystrophy at age 2. Muscle Nerve 1992; 15:52-56
12. Adnet PJ, Krivosic-Horber M, Krivosic I, Haudecoeur G, Reyford HG, Adamantidis MM, Medahoui H. Viability criterion on muscle bundles used in the in vitro contracture test in patients with neuromuscular diseases. J Anaesth 1994;72:93-97 (Pubitemid 24023572)
13. Robinson RL, Curran JL, Ellis FR, Halsall PJ, Hall WJ, Hopkins PM, Iles DE, West SP, Shaw MA. Multiple interacting gene products may influence susceptibility to malignant hyperthermia. Ann Hum Genet 2000;64:307-320
14. Jurkat-Rott K, McCarthy T, Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 2000; 23:4-17